

# **Natco Pharma Limited**

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243 CIN : L24230TG1981PLC003201, www.natcopharma.co.in

May 22, 2021

Corporate Relationship Department M/s. BSE Ltd. Dalal Street, Fort <u>Mumbai 400 001</u> Manager – Listing M/s. National Stock Exchange of India Ltd "Exchange Plaza", Bandra – Kurla Complex Bandra (E) <u>Mumbai 400 051</u>

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclose herewith the Press Release for your information.

Thanking you

Yours faithfully For NATCO Pharma Limited MAnarreyona

M. Adinarayana Company Secretary & Vice President (Legal and Corp Affairs



**Natco Pharma Limited** 

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243 CIN : L24230TG1981PLC003201, www.natcopharma.co.in

## Ref: PR/ 7 /2021-22

### Press Release

### NATCO receives USFDA approval for Lenalidomide Capsules

#### Hyderabad, India, May 22<sup>nd</sup>, 2021

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce the final approval of its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules, 5mg, 10mg, 15mg, and 25mg strengths, from the U.S. Food and Drug Administration (FDA), and the tentative approval of the 2.5mg and 20mg strengths.

NATCO, along with its marketing partner Arrow International Limited (a U.S. affiliate of Teva Pharmaceutical Industries Ltd), previously settled the Paragraph IV litigation related to the product with Celgene (now part of Bristol-Myers Squibb), who sells the product under the brand-name REVLIMID®. NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.

\*All brand names and trademarks are the property of their respective owners.

Forwarded for favour of publication For NATCO Pharma Limited

Manayene

M Adinarayana Company Secretary & Vice President (Legal & Corp Affairs)